Any current/future new fundraising through debt or equity?

There are no explicit mentions of any current or future fundraising plans through debt or equity in the provided transcript. The company discusses existing debt levels (gross debt around INR 650 crores, net debt to equity ratio expected around 0.3-0.35 post capex). Capex projects like Atali (INR 450 crores total) and Xanthine (INR 150 crores) expansions are underway, with no direct indication of new equity or debt raising for these. Management expects to manage capex internally, as no mention of fresh fundraises is made. Overall, the discussion centers on operational performance, capex executi

Future growth expectations in sales/revenue/volumes?

CDMO business expected to see good growth; FY '27 guidance to be prepared post budgeting in March 2026. Potential for substantial growth due to small base and possible 1-2 good commercial opportunities. CDMO sales target: INR 1,000 crores; aiming for similar growth in FY '27 as FY '26. Increasing wallet share with innovator partners; around 7-8 projects anchor 80% of CDMO sales. New commercial molecules (from ~28 to 40) progressing to scale up revenues. Xanthine segment planning 25-30%+ volume growth next year; with 5-10% realization improvement due to China-related dynamics. API segment curre

Future growth expectations in earnings/operating earnings/profits/EPS?

The company anticipates good growth in the CDMO business for FY '27, with budgeting and detailed guidance to be finalized by March. CDMO sales target is INR 1,000 crores, with similar growth expected in FY '27 as FY '26. EBITDA for FY '26 is expected to be largely in line with last year with marginal growth; a strong mid-to-long term growth trajectory is anticipated. Recent margin pressures in API segment due to pricing degrowth and slow volume growth; capacity expansions and product launches are expected to aid recovery and growth. Atali plant expansion and Xanthine plant ramp-ups projected t

Current/ Expected Orderbook/ Pending Orders?

The company has single purchase orders (POs) in the range of single-digit millions of dollars, indicating sizeable orders. At the end of FY '25, the company had 21 CDMO customers; the number is expected to increase in calendar year 2026. A good number of new CDMO inquiries have been generated starting this year, with hopes to win multiple RFPs. The CDMO business pipeline includes 5-7 significant projects anchoring 80% of sales, with a dynamic list of about 60 projects being tracked. There is a mix of customers including innovators, CDMO partners, smaller biotechs, and traders. Some projects ha

IN US

Sale is live|00:00:00left today

Aarti Pharmalabs LtdQ4 FY27Pharmaceuticals & Biotechnology

Aarti Pharmalabs Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹691P/E: 29.9Market Cap: ₹6.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→CDMO business expected to see good growth; FY '27 guidance to be prepared post budgeting in March 2026.
→Potential for substantial growth due to small base and possible 1-2 good commercial opportunities.
→CDMO sales target: INR 1,000 crores; aiming for similar growth in FY '27 as FY '26.
→Increasing wallet share with innovator partners; around 7-8 projects anchor 80% of CDMO sales.
→New commercial molecules (from ~28 to 40) progressing to scale up revenues.
→Xanthine segment planning 25-30%+ volume growth next year; with 5-10% realization improvement due to China-related dynamics.
→API segment currently slow with some degrowth; expected to recover with new product launches and capacity expansion (including Atali plant).
→EBITDA growth anticipated to be flat to moderate in FY '26 but with strong mid-to-long-term growth trajectory.
→Expansion projects (Atali, Xanthine) to contribute progressively from FY '27 onwards.

Margin guidance

Category 3

→The company anticipates good growth in the CDMO business for FY '27, with budgeting and detailed guidance to be finalized by March.
→CDMO sales target is INR 1,000 crores, with similar growth expected in FY '27 as FY '26.
→EBITDA for FY '26 is expected to be largely in line with last year with marginal growth; a strong mid-to-long term growth trajectory is anticipated.
→Recent margin pressures in API segment due to pricing degrowth and slow volume growth; capacity expansions and product launches are expected to aid recovery and growth.
→Atali plant expansion and Xanthine plant ramp-ups projected to improve production capacity and margins progressively in FY '27.
→EBITDA margins seen above 25% possible when CDMO/CMO contribution grows further.
→Operational expenses from new expansions (Atali, Xanthine) may normalize once ramp-up stabilizes.
→Overall, growth driven by increased wallet share in CDMO, pipeline commercializations, and capacity expansions.

3 more insights locked — sign up free to unlock

Fundraise plans

→There are no explicit mentions of any current or future fundraising plans through debt or equity in the provided transcript.
→The company discusses existing debt levels (gross debt around INR 650 crores, net debt to equity ratio expected around 0.3-0.35 post capex).
→Capex projects like Atali (INR 450 crores total) and Xanthine (INR 150 crores) expansions are underway, with no direct indication of new equity or debt raising for these.
→Management expects to manage capex internally, as no mention of fresh fundraises is made.
→Overall, the discussion centers on operational performance, capex execution, and business growth, with no clear signals of additional fundraising plans.

Order book

→The company has single purchase orders (POs) in the range of single-digit millions of dollars, indicating sizeable orders.
→At the end of FY '25, the company had 21 CDMO customers; the number is expected to increase in calendar year 2026.
→A good number of new CDMO inquiries have been generated starting this year, with hopes to win multiple RFPs.
→The CDMO business pipeline includes 5-7 significant projects anchoring 80% of sales, with a dynamic list of about 60 projects being tracked.
→There is a mix of customers including innovators, CDMO partners, smaller biotechs, and traders.
→Some projects have wallet shares of 60-70%, indicating deep involvement in product manufacturing.
→Large single-product opportunities are in the pipeline, with potential turnovers exceeding INR100-150 crores.
→Bulk of CDMO shipments for newer products are expected in the last quarter, reflecting order execution scaling up.

Capex plans

Yes

- Aarti Pharmalabs plans capital expenditure (capex) for FY27-FY28 focused on expansions: - Atali site: At least one new manufacturing block is planned for FY27 with capex approval forthcoming; described as not a large capex. - Xanthine site: Approved capex is around INR150 crores for both sites combined, with an ongoing capacity increase targeting 9,000 tonnes per annum by end of Q4. - Capex at Atali includes INR450 crores total: - INR300 crores commercialized. - INR150 crores balance remaining. - Expansion plans tied to growth visibility in CDMO business, expecting strong ramp-up post-launch of new blocks. - Debottlenecking plans for steroid and oncology blocks to enhance capacity are also underway. Overall, strategic investments focus on expanding manufacturing capacity to support growing CDMO and intermediate/API businesses.

How does Aarti Pharmalabs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Aarti Pharmalabs Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Aarti Pharmalabs Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio